Kooth plc

AIM:KOO Stock Report

Market Cap: UK£60.4m

Kooth Valuation

Is KOO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KOO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KOO (£1.66) is trading below our estimate of fair value (£15.6)

Significantly Below Fair Value: KOO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KOO?

Key metric: As KOO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for KOO. This is calculated by dividing KOO's market cap by their current earnings.
What is KOO's PE Ratio?
PE Ratio14.1x
EarningsUK£4.28m
Market CapUK£60.38m

Price to Earnings Ratio vs Peers

How does KOO's PE Ratio compare to its peers?

The above table shows the PE ratio for KOO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.4x
IDHC Integrated Diagnostics Holdings
13.6x23.7%US$225.8m
PHSC PHSC
11.8xn/aUK£2.9m
INS Instem
59.8xn/aUK£199.6m
TSTL Tristel
32.3x17.5%UK£209.7m
KOO Kooth
14.1x11.0%UK£60.4m

Price-To-Earnings vs Peers: KOO is good value based on its Price-To-Earnings Ratio (14.1x) compared to the peer average (19.2x).

Price to Earnings Ratio vs Industry

How does KOO's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
KOO 14.1xIndustry Avg. 18.6xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: KOO is good value based on its Price-To-Earnings Ratio (14.1x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is KOO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KOO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.1x
Fair PE Ratio20.7x

Price-To-Earnings vs Fair Ratio: KOO is good value based on its Price-To-Earnings Ratio (14.1x) compared to the estimated Fair Price-To-Earnings Ratio (20.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KOO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£1.66
UK£5.21
+214.7%
13.9%UK£5.90UK£3.75n/a6
Nov ’25UK£1.74
UK£5.21
+199.3%
13.9%UK£5.90UK£3.75n/a6
Oct ’25UK£3.20
UK£5.42
+69.3%
6.8%UK£5.90UK£5.00n/a6
Sep ’25UK£3.26
UK£5.28
+62.1%
11.0%UK£5.90UK£4.20n/a6
Aug ’25UK£3.23
UK£5.28
+63.6%
11.0%UK£5.90UK£4.20n/a6
Jul ’25UK£2.93
UK£5.11
+74.3%
12.0%UK£5.80UK£4.20n/a5
Jun ’25UK£3.11
UK£5.17
+66.3%
11.2%UK£5.80UK£4.20n/a6
May ’25UK£2.84
UK£5.17
+82.2%
11.2%UK£5.80UK£4.20n/a6
Apr ’25UK£2.70
UK£5.17
+91.6%
11.2%UK£5.80UK£4.20n/a6
Mar ’25UK£2.90
UK£5.03
+73.5%
9.9%UK£5.65UK£4.20n/a6
Feb ’25UK£2.79
UK£5.20
+86.3%
6.9%UK£5.65UK£4.64n/a5
Jan ’25UK£2.97
UK£5.18
+74.5%
7.4%UK£5.65UK£4.57n/a5
Dec ’24UK£2.93
UK£5.18
+76.9%
7.4%UK£5.65UK£4.57n/a5
Nov ’24UK£3.00
UK£5.18
+72.8%
7.4%UK£5.65UK£4.57UK£1.745
Oct ’24UK£3.01
UK£5.18
+72.2%
7.4%UK£5.65UK£4.57UK£3.205
Sep ’24UK£3.29
UK£5.24
+59.3%
9.1%UK£5.65UK£4.57UK£3.263
Aug ’24UK£3.55
UK£5.24
+47.6%
9.1%UK£5.65UK£4.57UK£3.233
Jul ’24UK£2.50
UK£3.35
+34.0%
20.1%UK£3.90UK£2.40UK£2.933
Jun ’24UK£2.47
UK£3.35
+35.6%
20.1%UK£3.90UK£2.40UK£3.113
May ’24UK£2.53
UK£3.35
+32.4%
20.1%UK£3.90UK£2.40UK£2.843
Apr ’24UK£2.33
UK£3.35
+44.1%
20.1%UK£3.90UK£2.40UK£2.703
Mar ’24UK£1.78
UK£3.35
+88.2%
20.1%UK£3.90UK£2.40UK£2.903
Feb ’24UK£1.64
UK£3.35
+104.3%
20.1%UK£3.90UK£2.40UK£2.793
Jan ’24UK£1.40
UK£3.35
+140.1%
20.1%UK£3.90UK£2.40UK£2.973
Dec ’23UK£1.36
UK£3.35
+146.3%
20.1%UK£3.90UK£2.40UK£2.933
Nov ’23UK£1.13
UK£3.35
+197.8%
20.1%UK£3.90UK£2.40UK£3.003

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.92

7D

-4.8%

1Y

-9.6%

Guerbet

€339.2m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

7D

-9.8%

1Y

50.2%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.06

7D

-6.1%

1Y

5.3%